Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer.

Ninety six colorectal carcinoma patients were included in a randomised study, 48 were treated with Ukrain monotherapy (15 with metastatic and 33 with nonmetastatic colorectal carcinoma) and 48 with 5-fluorouracil (5-FU) and X-ray therapy (the same randomised groups). The results of therapy including clinical, haematological, immunological and biochemical parameters show that Ukrain has favourable properties in the treatment of colon and rectal cancer as a monotherapy because of its malignotoxic and immunomodulating action. Objective response rate in the group of metastatic colorectal cancer treated by Ukrain was 40%. There was no registered tumour regression in the group treated by 5-FU. Operability is strongly facilitated by pretreatment with Ukrain. The survival rate (up to 21 months) in the Ukrain-treated patients with nonmetastatic colorectal cancer was 78.6% and 33.3% in a corresponding control group. Ukrain is a new effective drug in the therapy of colorectal cancer. It can be useful both for the therapy of metastatic colorectal cancer and for neoadjuvant therapy of nonmetastatic colorectal cancer.

Ukrain therapy of recurrent breast cancer with lung metastases (case report).

A recurrent breast cancer with lung metastases was treated with the new anticancer drug Ukrain. The first two courses led to subjective improvement of the general condition as well as work capability; appetite improved and shortness of breath disappeared. After the sixth course of Ukrain therapy objective improvement was found clinically on X-ray, in haematological and biochemical data and improved tumour markers. Lymph nodes and lung metastases disappeared. The patient showed a full clinical remission.

Combined therapy with Ukrain and chemotherapy in ovarian cancer (case report).

A patient with adenocarcinoma in the right ovary with lymphangitis carcinomatosa, staged as G II-G III pT3, pNX, pMX, was treated after palliative surgery by chemotherapy and, simultaneously, with Ukrain. Two and a half years after treatment the patient is without any signs of tumour recurrence. Her condition is excellent.

Ukrain treatment in carcinoma of the cervix (case report).

A grade IV Papanicolaou cervical cancer was treated with endocervical cone biopsy (electrocoagulation) in a 28 year-old lady. Three years later examination revealed cervical carcinoma in situ and a conization was recommended, which the patient refused. She was treated with Ukrain instead. The grading regressed steadily and after one year of Ukrain therapy all stagings were normal. Three years after the start of Ukrain therapy she gave birth to a healthy child. Eight years later she has no recurrence and is healthy.

Ukrain treatment in a patient with non-seminomatous germ-cell tumour of testis (case report).

A 31 year old patient with non-seminomatous germ-cell tumour of the testis was treated with Ukrain following operation and gamma-radiotherapy. 20 mg Ukrain ampoules were injected i.v. twice weekly with a total dose of 200 mg for each of three courses of treatment. Within the period of 24 months observation no recurrence or metastases were found. The results testify that Ukrain in complex treatment of patients with non-seminomatous germ-cell tumours of the testis can contribute to optimisation of immune status which improves the prognoses and results of treatment.

Ukrain in the treatment of urethral recurrent carcinoma (case report).

In a patient with low grade differentiated urethral carcinoma (histologically: urothelial carcinoma G2 and G3, pT1 with low grade differentiation) operation was carried out, with recurrence after two months. Instead of reoperation the patient was given Ukrain as monotherapy. No carcinoma was detected four months later by histological examination or during examinations three years later.

Ukrain therapy in a frontal anaplastic grade III astrocytoma (case report).

Ukrain, a semisynthetic thiophosphoric acid compound of alkaloid chelidonine from Chelidonium majus L. (1) causes regression of various tumours. Among other effects, its action seems to depend on the stimulation of the immune system which very often is deficient in cancer patients. Its use in a patient with subtotal extirpation of a frontal anaplastic grade III astrocytoma seems to have reduced growth speed significantly.

Ukrain therapy of a recurrent astrocytoma of the optic nerve (case report).

An eight year old girl was twice operated (1989 and 1991) for a Grade I astrocytoma of the chiasma. Because of early recurrence and the fact that the tumour could only be extirpated subtotally Ukrain monotherapy was initiated.